Last updated on February 2019

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation


Brief description of study

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who are refractory to or have relapsed after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy. In addition, this study will evaluate safety as well as determine the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.

Detailed Study Description

Participants considered an adult according to local regulations at the time of signing informed consent will be randomized in a 1:1 ratio to receive ASP2215 or salvage chemotherapy. Participants will enter the screening period up to 14 days prior to the start of treatment. Prior to randomization, the investigator will preselect a salvage chemotherapy regimen for each participant; options will include low-dose cytarabine (LoDAC), mitoxantrone, etoposide and intermediate-dose cytarabine (MEC) or fludarabine, high-dose cytarabine and granulocyte colony-stimulating factor (FLAG). The randomization will be stratified by response to first-line therapy and preselected salvage chemotherapy. Participants will be administered treatment over continuous 28-day cycles.

Among the participants, approximately 20 Chinese participants who are randomized into the ASP2215 arm will be allocated to the pharmacokinetic (PK) cohort. Participants in the PK cohort will be requested to be hospitalized from the date of randomization (Day 1) to at least the completion of all the assessments planned on Day 2. All participants in the PK cohort will undergo blood sampling for PK measurement of ASP2215. Participants in PK cohort will be administered the study drug in the same manner and undergo the same efficacy and safety assessments as other participants except for blood sampling for additional PK measurements.

Clinical Study Identifier: NCT03182244

Find a site near you

Start Over

Site MY306

Ampang, Malaysia
  Connect »

Site MY301

Johor Bahru, Malaysia
  Connect »

Site MY302

Kuala Lumpur, Malaysia
  Connect »

Site MY303

Pulau Pinang, Malaysia
  Connect »

Site RU501

Saint Petersburg, Russian Federation
  Connect »

Site SG402

Singapore, Singapore
  Connect »

Site TH204

Chiang Mai, Thailand
  Connect »

Site MY305

George Town, Malaysia
  Connect »

Site RU506

Kemerovo, Russian Federation
  Connect »

Site RU504

Krasnoyarsk, Russian Federation
  Connect »

Site RU503

Tula, Russian Federation
  Connect »

Site SG401

Singapore, Singapore
  Connect »

Site TH201

Khon Kaen, Thailand
  Connect »

Site CN101

Tianjin, China
  Connect »

Site MY304

Kota Kinabalu, Malaysia
  Connect »

Site CN109

Beijing, China
  Connect »

Site CN110

Beijing, China
  Connect »

Site CN113

Zhengzhou, China
  Connect »

Site RU502

Saint-Petersburg, Russian Federation
  Connect »

Site TH205

Bangkok, Thailand
  Connect »

Site CN131

Beijing, China
  Connect »

Site CN120

Changsha, China
  Connect »

Site CN123

Huangpu Qu, China
  Connect »

Site CN128

Nanjing, China
  Connect »

Site CN129

Shanghai, China
  Connect »

Site CN126

Yangzhou, China
  Connect »

Site RU507

Saint Petersburg, Russian Federation
  Connect »

Site CN114

Guangzhou, China
  Connect »

Site CN121

Guangzhou, China
  Connect »

Site TH203

Bangkok, Thailand
  Connect »

Site CN103

Beijing, China
  Connect »

Site CN130

Guiyang City, China
  Connect »

Site SG403

Singapore, Singapore
  Connect »

Site CN102

Guangzhou, China
  Connect »

Site CN107

Hangzhou, China
  Connect »

Site TH202

Khon Kaen, Thailand
  Connect »

Site CN116

Changchun, China
  Connect »

Site CN133

Lanzhou, China
  Connect »

Site CN125

Shenyang, China
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.